0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Changes recommended in use of human diploid cell rabies vaccine

Charles Marwick
JAMA. 1985;254(1):13-14. doi:10.1001/jama.1985.03360010015002.
Text Size: A A A
Published online

ABSTRACT

In June 1980, a new rabies vaccine, using a virus cultivated on human cells, was licensed. Now, five years later, some changes have been recommended in how it is used.

At the time of its licensing at the beginning of the decade, the new vaccine was hailed as a major advance. This opinion was based principally on the heightened immunogenicity of the vaccine, which made it possible to reduce the number of doses for both pre-exposure prophylaxis and post-exposure treatment, compared with the then-available rabies vaccine. The latter employed virus cultivated on duck embryo tissues.

Since then, about 400,000 doses of the newer human diploid cell vaccine have been given to about 100,000 persons in the United States, according to the Centers for Disease Control in Atlanta. But recently, a problem with the new vaccine has emerged. Hypersensitivity reactions have been reported in some individuals, mostly among those given routine

Topics

Sign in to download this free article PDF

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in to download this free article PDF

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();